Neoadjuvant Treatment of Mismatch Repair–Deficient Colon Cancer — Clinically Meaningful?
Mené sur 115 patients atteints d'un cancer du côlon de stade localement avancé et présentant des déficiences du système MMR (durée médiane de suivi : 26 mois), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans maladie à 3 ans, et la toxicité d'une immunothérapie néoadjuvante combinant nivolumab et ipilimumab
In this issue of the Journal, Chalabi and colleagues1 present findings from a large study showing impressive pathological responses of mismatch repair–deficient (dMMR) early-stage colon cancers to neoadjuvant dual immune checkpoint blockade followed by surgical resection. This study was started as a proof-of-principle pilot study with just 1 month of checkpoint blockade therapy followed by standard surgical resection. In the expanded cohort that is described in the current article, approximately two thirds of the patients had a pathological complete response (no residual viable tumor). The authors are to be congratulated on these results, which further highlight the sensitivity of dMMR (...)
New England Journal of Medicine , éditorial, 2023